330 related articles for article (PubMed ID: 16315018)
1. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
2. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
4. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
5. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
6. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
Ma L; Guo Q; Ma Y; Liu FR; Shen XY
Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
[TBL] [Abstract][Full Text] [Related]
8. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.
Qian ZR; Sano T; Yoshimoto K; Yamada S; Ishizuka A; Mizusawa N; Horiguchi H; Hirokawa M; Asa SL
Lab Invest; 2005 Apr; 85(4):464-73. PubMed ID: 15711568
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
13. [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
Ma L; Liu FR; Zhang SL
Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):785-7. PubMed ID: 16545186
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
18. High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer.
Yeo W; Wong WL; Wong N; Law BK; Tse GM; Zhong S
Pathology; 2005 Apr; 37(2):125-30. PubMed ID: 16028839
[TBL] [Abstract][Full Text] [Related]
19. Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer.
Rezk NA; Mohamed RH; Alnemr AA; Harira M
Appl Biochem Biotechnol; 2018 May; 185(1):153-162. PubMed ID: 29098560
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
